Stockscreener 앱 받기
71.50
0.20%
-0.14
시간 외 거래:
72.00
0.50
+0.70%
전일 마감가:
$71.64
열려 있는:
$71.23
하루 거래량:
1.47M
Relative Volume:
0.60
시가총액:
$11.40B
수익:
$705.14M
순이익/손실:
$-453.90M
주가수익비율:
-23.52
EPS:
-3.04
순현금흐름:
$-551.29M
1주 성능:
-1.23%
1개월 성능:
+16.53%
6개월 성능:
+146.30%
1년 성능:
+84.85%
1일 변동 폭
$70.60
$71.98
1주일 범위
$70.47
$74.42
52주 변동 폭
$23.95
$74.42
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
명칭
Ionis Pharmaceuticals Inc
전화
(760) 931-9200
주소
2855 GAZELLE COURT, CARLSBAD, CA
IONS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
71.50 | 11.42B | 705.14M | -453.90M | -551.29M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.44 | 109.29B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.90 | 62.13B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
584.74 | 61.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
814.17 | 51.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
313.54 | 34.68B | 4.56B | -176.77M | 225.30M | -1.7177 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-08 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2025-09-26 | 업그레이드 | Goldman | Sell → Neutral |
| 2025-09-03 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-31 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-01 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2025-04-07 | 개시 | H.C. Wainwright | Buy |
| 2025-03-31 | 개시 | Redburn Atlantic | Neutral |
| 2024-08-02 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-07-24 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-07-16 | 재개 | Jefferies | Buy |
| 2024-06-14 | 업그레이드 | Bernstein | Underperform → Mkt Perform |
| 2024-04-10 | 업그레이드 | Wolfe Research | Peer Perform → Outperform |
| 2024-01-02 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-10-23 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2023-09-29 | 개시 | Raymond James | Strong Buy |
| 2023-07-31 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-06-07 | 재개 | Piper Sandler | Overweight |
| 2023-05-04 | 업그레이드 | Citigroup | Sell → Neutral |
| 2023-03-21 | 개시 | Bernstein | Underperform |
| 2022-12-21 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-09-09 | 재개 | Morgan Stanley | Overweight |
| 2022-07-18 | 재개 | Oppenheimer | Outperform |
| 2022-03-31 | 재개 | Piper Sandler | Overweight |
| 2022-03-01 | 개시 | Citigroup | Sell |
| 2022-03-01 | 개시 | Guggenheim | Buy |
| 2022-02-01 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2021-12-14 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2021-05-07 | 업그레이드 | UBS | Sell → Neutral |
| 2021-03-01 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2020-12-16 | 개시 | UBS | Sell |
| 2020-12-15 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2020-09-14 | 재개 | JP Morgan | Neutral |
| 2020-09-02 | 개시 | The Benchmark Company | Hold |
| 2020-06-01 | 재개 | Oppenheimer | Outperform |
| 2020-05-13 | 개시 | RBC Capital Mkts | Outperform |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2019-12-13 | 개시 | Oppenheimer | Outperform |
| 2019-11-13 | 개시 | BofA/Merrill | Buy |
| 2019-11-07 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2019-09-10 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2018-08-08 | 재확인 | Stifel | Hold |
| 2018-08-07 | 재확인 | Stifel | Hold |
| 2018-05-08 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2017-10-06 | 재개 | Goldman | Sell |
| 2017-08-17 | 개시 | Evercore ISI | Outperform |
| 2017-08-09 | 재확인 | Stifel | Hold |
| 2017-03-10 | 다운그레이드 | Goldman | Neutral → Sell |
| 2016-12-28 | 재확인 | BMO Capital Markets | Outperform |
| 2016-12-27 | 재확인 | Leerink Partners | Mkt Perform |
모두보기
Ionis Pharmaceuticals Inc 주식(IONS)의 최신 뉴스
Ionis Pharmaceuticals (IONS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance
What is the fair value estimate for Ionis Pharmaceuticals Inc. (ISI) stock in 20252025 Fundamental Recap & High Accuracy Investment Signals - newser.com
Published on: 2025-10-21 21:59:51 - newser.com
Can Ionis Pharmaceuticals Inc. (ISI) stock sustain revenue momentumBond Market & Real-Time Stock Entry Alerts - newser.com
Sector ETF performance correlation with Ionis Pharmaceuticals Inc.Portfolio Risk Summary & Technical Pattern Based Buy Signals - newser.com
Ionis CEO Brett P. Monia receives 2025 Lifetime Achievement Award from the Oligonucleotide Therapeutics Society - Business Wire
Is Ionis Pharmaceuticals Inc. stock poised for growth2025 Price Momentum & Weekly Hot Stock Watchlists - newser.com
Published on: 2025-10-21 01:16:00 - newser.com
Ionis Pharmaceuticals Inc. stock trend outlook and recovery pathJuly 2025 Sentiment & Scalable Portfolio Growth Ideas - newser.com
Can Ionis Pharmaceuticals Inc. stock resist market sell offsNew Guidance & Community Trade Idea Sharing - newser.com
Capricorn Buys New Stake in Ionis Pharmaceuticals (IONS) With 163,000 Shares - The Motley Fool
News impact scoring models applied to Ionis Pharmaceuticals Inc.July 2025 Sentiment & Accurate Technical Buy Alerts - newser.com
Is Ionis Pharmaceuticals Inc. (ISI) stock resilient in recession scenariosIPO Watch & Verified Technical Signals - nchmf.gov.vn
Can you recover from losses in Ionis Pharmaceuticals Inc.Portfolio Return Report & Smart Allocation Stock Tips - newser.com
Is Ionis Pharmaceuticals Inc. stock ready for breakoutJuly 2025 Outlook & Consistent Profit Alerts - newser.com
Will Ionis Pharmaceuticals Inc. stock deliver better than expected guidanceTrade Ideas & Verified Technical Signals - newser.com
Is Ionis Pharmaceuticals Inc. building a consolidation baseEarnings Performance Report & Weekly High Return Stock Forecasts - newser.com
Why ETFs are accumulating Ionis Pharmaceuticals Inc. (ISI) stockGold Moves & Safe Capital Allocation Plans - newser.com
What recovery options are there for Ionis Pharmaceuticals Inc.July 2025 Setups & Detailed Earnings Play Strategies - newser.com
Should Ionis Pharmaceuticals' (IONS) Raised Revenue Guidance and Strong Q2 Results Prompt Investor Action? - Sahm
Can Ionis Pharmaceuticals Inc. stock weather global recessionTrade Exit Summary & Technical Entry and Exit Tips - nchmf.gov.vn
Layoff Watch: Can Ionis Pharmaceuticals Inc. stock weather global recessionJuly 2025 PostEarnings & Stepwise Trade Signal Guides - nchmf.gov.vn
Will Ionis Pharmaceuticals Inc. stock sustain high P E ratiosRecession Risk & Advanced Swing Trade Entry Plans - nchmf.gov.vn
Bear Alert: Is Ionis Pharmaceuticals Inc. stock a top pick in earnings seasonQuarterly Trade Report & Smart Money Movement Tracker - nchmf.gov.vn
Hedge Fund and Insider Trading News: Scott Bessent, Paul Tudor Jones, Crispin Odey, Ken Griffin, Millennium Management, Ionis Pharmaceutical Inc (IONS), Chicago Atlantic Real Estate Finance Inc (REFI), and More - Insider Monkey
CapEx per share of Ionis Pharmaceuticals, Inc. – DUS:ISI - TradingView
Ionis Pharmaceuticals Insider Sold Shares Worth $1,723,987, According to a Recent SEC Filing - MarketScreener
Ionis Pharmaceuticals director Parshall sells $358,721 in stock By Investing.com - Investing.com Australia
Ionis Pharmaceuticals EVP Birchler sells $1.72m in shares By Investing.com - Investing.com Australia
Insider Sell Alert: B Parshall Sells 5,000 Shares of Ionis Pharm - GuruFocus
Ionis Pharma EVP Devers sells shares worth $530,636 By Investing.com - Investing.com Canada
Ionis Pharmaceuticals EVP research, Eric Swayze, sells $3901 in IONS stock - Investing.com Nigeria
Ionis Pharmaceuticals EVP Birchler sells $1.72m in shares - Investing.com
Morgan Stanley Raises Price Target for Ionis Pharmaceuticals (IO - GuruFocus
Ionis Pharmaceuticals Hits New 52-Week High of $72.15 - Markets Mojo
Ionis Pharmaceuticals Hits New 52-Week High of $73.92 - Markets Mojo
Morgan Stanley Raises Price Target on Ionis Pharmaceuticals to $90 From $86, Keeps Overweight Rating - MarketScreener
Ionis to hold third quarter 2025 financial results webcast - FinancialContent
Lobbying Update: $140,000 of IONIS PHARMACEUTICALS INC. lobbying was just disclosed - Quiver Quantitative
Ionis Pharmaceuticals Inc (IONS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.71%
0.87%
자본화:
|
볼륨(24시간):